Moderna provides updates on mRNA vaccine platform

By The Science Advisory Board staff writers

April 14, 2021 -- Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources to accelerate the development of its mRNA vaccine platforms.

In addition to highlighting the advantages of these types of vaccines, the company announced that its seven-month data for its cytomegalovirus (CMV) vaccine candidate show that all its measures of neutralizing antibody geometric mean titers (GMTs) are at or above CMV seropositive baselines. A phase III study will evaluate the vaccine in about 8,000 participants in 2021.

Also, interim analysis of a phase I vaccine candidate (mRNA-1345) for respiratory syncytial virus (RSV) shows a greater than elevenfold increase in RSV-neutralizing antibodies in individuals between the ages of 18 and 49. Participants tolerated 50-µg and 100-µg dose levels well.

Lastly, Moderna plans to begin a phase I study evaluating HIV mRNA vaccine candidates, as well as a phase I clinical study of an mRNA flu vaccine candidate in 2021. To date, the company has started clinical trials for 14 different mRNA vaccine candidates.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here